Dominik Sonanini

Dominik Sonanini

Auto-generated profile, based on publicly available information

Dominik Sonanini

Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University Hospital Tübingen, Eberhard Karls University Tübingen; Tübingen, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2024 in Biomarker Research
Verified
Journal Article
Open access
PDF file
DSDominik Sonanini
Dominik Sonanini
JSJohannes Schwenck
Johannes Schwenck
SBSimone Blaess
Simone Blaess
JSJulia Schmitt
Julia Schmitt
AMAndreas Maurer
Andreas Maurer
BPBernd J. Pichler
Bernd J. Pichler
Cell- and antibody-based CD19-directed therapies have demonstrated great potential for treating B-cell non-Hodgkin lymphoma (B-NHL). However, all these approaches suffer from limited response rates and considerable toxicity. Until now, therapy decisions have been routinely based on histopathological CD19 staining of a single lesion at initial diagnosis or relapse, disregarding heterogeneity and temporal alterations in antigen expression. To visualize in vivo CD19 expression noninvasively, we radiolabeled anti-human CD19 monoclonal antibodies with copper-64 (64Cu-αCD19) for positron emission tomography (CD19-immunoPET). 64Cu-αCD19 specifically bound to subcutaneous Daudi xenograft mouse models in vivo. Importantly, 64Cu-αCD19 did not affect the anti-lymphoma cytotoxicity of CD19 CAR-T cells in vitro. Following our preclinical validation, 64Cu-αCD19 was injected into four patients with follicular lymphoma, diffuse large B-cell lymphoma or mantle zone lymphoma. We observed varying 64Cu-αCD19 PET uptake patterns at different lymphoma sites, both within and among patients, correlating with ex vivo immunohistochemical CD19 expression. Moreover, one patient exhibited enhanced uptake in the spleen compared to that in patients with prior B-cell-depleting therapy, indicating that 64Cu-αCD19 is applicable for identifying B-cell-rich organs. In conclusion, we demonstrated the specific targeting and visualization of CD19+ B-NHL in mice and humans by CD19-immunoPET. The intra- and interindividual heterogeneous 64Cu-αCD19 uptake patterns of lymphoma lesions indicate variability in CD19 expression, suggesting the potential of CD19-immunoPET as a novel tool to guide CD19-directed therapies.

27 June 2025 in Science Advances
Verified
Journal Article
Open access
SPStefania Pezzana
Stefania Pezzana
SBSimone Blaess
Simone Blaess
BTBjoern Traenkle
Bjoern Traenkle
ASAnna Schaefer
Anna Schaefer
LRLara Ruoff
Lara Ruoff
DSDominik Sonanini
Dominik Sonanini
CD4 + T cells are crucial in shaping response and resistance to immunotherapy. To enhance our understanding of their multifaceted functions, we developed copper-64–radiolabeled nanobodies targeting the human CD4 receptor ( 64 Cu-CD4-Nb1) for positron emission tomography (PET). In human CD4-receptor knock-in mice, 64 Cu-CD4-Nb1 specifically accumulated in different orthotopic tumors, correlating with histological CD4 + cell densities. Based on intratumoral CD4 + cell distribution patterns within the core and periphery, we distinguished responders to combined αPD-1/4-1BB antibodies early on-treatment. CD4-PET identified resistance to αPD-1 monotherapy, which was mitigated by adding regulatory T cell–depleting α4-1BB antibodies. Patients with early-stage non–small cell lung cancer who relapsed after neoadjuvant αPD-L1 therapy revealed low CD4 + T cell densities in the tumor core. In human and mouse tumor tissues, regulatory T cells correlated with CD4 + cell densities. Thus, visualizing the spatial distribution patterns of CD4 + cells by PET offers mechanistic insights into CD4-mediated therapy efficacy, with great potential for guiding combinatorial immunotherapies in patients with cancer.

1 January 2024 in Theranostics
Verified
Journal Article
Open access
PDF file
SPStefania Pezzana
Stefania Pezzana
SBSimone Blaess
Simone Blaess
JKJule Kortendieck
Jule Kortendieck
NHNicole Hemmer
Nicole Hemmer
BTBredi Tako
Bredi Tako
DSDominik Sonanini
Dominik Sonanini
Increasing evidence emphasizes the pivotal role of CD4+ T cells in orchestrating cancer immunity. Noninvasive in vivo imaging of the temporal dynamics of CD4+ T cells and their distribution patterns might provide novel insights into their effector and regulator cell functions during cancer immunotherapy (CIT).

28 August 2025 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
MSMarieke A. Stammes
Marieke A. Stammes
GKGerrit Koopman
Gerrit Koopman
TWTeresa R. Wagner
Teresa R. Wagner
BTBjoern Traenkle
Bjoern Traenkle
PKPhilipp D. Kaiser
Philipp D. Kaiser
DSDominik Sonanini
Dominik Sonanini
Monitoring the presence and distribution of distinct immune cell populations is key in deciphering immunopathologic disease mechanisms. Considering the crucial role of myeloid cells in provoking hyperinflammatory responses associated with coronavirus disease 2019, a camelid-derived single-domain antibody specifically recognizing human signal-regulatory protein-α (SIRPα) as a biomarker for myeloid cells has been generated and radiolabeled with 64Cu, that is, [64Cu]copper-SIRPα-nanobody ([64Cu]Cu-SIRPα-Nb), for in vivo PET imaging. In this study, this PET tracer was used and validated to monitor the temporal dynamics of inflammatory processes during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in nonhuman primates. For further validation, the signal of [64Cu]Cu-SIRPα-Nb was compared with the signal of TSPO-targeting [18F]fluorine-N,N-diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo[1,5a]pyrimidin-3-yl)acetamide ([18F]F-DPA714). Methods: Six cynomolgus macaques (Macaca fascicularis) were experimentally infected with SARS-CoV-2 and subsequently monitored for 7 wk. We performed a baseline [64Cu]Cu-SIRPα-Nb PET/CT before infection, followed by repetitive PET/CT on days 3, 10, 24, and 52 after infection covering the head, thorax, and abdominal region. Of the 6 macaques, 3 underwent additional TSPO-targeting [18F]F-DPA714 PET/CT investigations at baseline and at days 2, 9, 23, and 51 after infection. Tracheal and nasal swabs were taken to monitor the course of infection, and changes in blood count and inflammatory mediators in the periphery blood were monitored. Results: Detection of subgenomic SARS-CoV-2 messenger RNA from tracheal and nasal swab samples confirmed viral infection of all animals. CT scans identified initial pulmonary lesions 2 days after infection. [64Cu]Cu-SIRPα-Nb PET/CT revealed increased tracer uptake in the mediastinal lymph nodes of all animals, but not in the lung lesions, 3 days after infection. [18F]F-DPA714 PET/CT showed increased uptake in both anatomically affected and unaffected lung tissues. The increased [64Cu]Cu-SIRPα-Nb uptake in the spleen and bone marrow of all animals was more pronounced 3 and 7 wk after infection. We detected individual differences in [64Cu]Cu-SIRPα-Nb uptake within the bone marrow and spleen, whereas [18F]F-DPA714 exhibited rather homogeneous uptake patterns. Conclusion: Our findings indicate that [64Cu]Cu-SIRPα-Nb is a versatile tool for quantitative monitoring of whole-body distribution, temporal distribution, and accumulation dynamics of myeloid cell subpopulations even in moderately inflamed tissues and affected lymphatic organs during SARS-CoV-2 infection. Visual Abstract

7 August 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SLSixing Li
Sixing Li
MNMarie-Aline Neveu
Marie-Aline Neveu
LKLaura Kuebler
Laura Kuebler
SPStefania Pezzana
Stefania Pezzana
ABAinara Barco-Tejada
Ainara Barco-Tejada
André F. MartinsAndré F. Martins
André F. Martins
The limited efficacy of immune checkpoint inhibitor (ICI) therapy in triple-negative breast cancer (TNBC) highlights the need for combination strategies that enhance antitumor responses. Sorafenib, a multikinase inhibitor with anti-angiogenic and immunomodulatory activity, represents a rational partner for ICI-based combination therapy. However, therapeutic responses to such combinations are biologically complex and cannot be fully characterized by any single biomarker or imaging modality. Here, we evaluated ICI therapy combined with sorafenib in the aggressive and ICI-refractory orthotopic 4T1 TNBC model. Therapeutic responses were assessed using a unique longitudinal multimodal imaging framework integrating [⁸⁹Zr]Zr-DFO–anti-CD8 minibody and [¹⁸F]FDG PET, as well as perfluorocarbon (PFC)-based ¹⁹F MRI and hyperpolarized ¹³C MRS, together with ex vivo analyses. Only the ICI–sorafenib combination suppressed tumor growth, whereas both monotherapies showed limited antitumor activity. Multimodal imaging, together with complementary ex vivo analyses, uncovered coordinated tumor microenvironment (TME) remodeling, including vascular normalization, elevated CD8⁺ cell presence with modest enrichment in the tumor center, delayed increase in phagocyte-associated ¹⁹F MRI signal coupled with reduced CD206⁺ cell infiltration, and sustained metabolic activity. These findings support ICI–sorafenib combination therapy as a promising therapeutic strategy for TNBC. Therapeutic efficacy reflected coordinated vascular, immune, and metabolic remodeling. This multimodal imaging framework enables non-invasive longitudinal monitoring of these complementary TME changes, providing a comprehensive strategy for treatment assessment in immunotherapy-based combination therapies. One Sentence Summary: Longitudinal multimodal imaging identified a multidimensional TME response signature of effective ICI-sorafenib therapy in TNBC.